131 related articles for article (PubMed ID: 20401980)
21. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
22. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies.
Zhang H; Shi YG; Woods JH; Watson SJ; Ko MC
Eur J Pharmacol; 2007 Sep; 570(1-3):89-96. PubMed ID: 17601558
[TBL] [Abstract][Full Text] [Related]
23. Sleep patterns in depression and anxiety: theory and pharmacological effects.
Sandor P; Shapiro CM
J Psychosom Res; 1994; 38 Suppl 1():125-39. PubMed ID: 7799244
[TBL] [Abstract][Full Text] [Related]
24. Role of the mesolimbic dopamine system in the mechanism of action of antidepressants.
Serra G; Collu M; D'Aquila PS; Gessa GL
Pharmacol Toxicol; 1992; 71 Suppl 1():72-85. PubMed ID: 1480562
[No Abstract] [Full Text] [Related]
25. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
Rothman RB; Gorelick DA; Heishman SJ; Eichmiller PR; Hill BH; Norbeck J; Liberto JG
J Subst Abuse Treat; 2000 Apr; 18(3):277-81. PubMed ID: 10742642
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of mu and kappa opioid antagonists on Fos-like immunoreactivity in extended amygdala.
Carr KD; Kutchukhidze N; Park TH
Brain Res; 1999 Mar; 822(1-2):34-42. PubMed ID: 10082881
[TBL] [Abstract][Full Text] [Related]
27. The role of the side chain in determining relative delta- and kappa-affinity in C5'-substituted analogues of naltrindole.
Black SL; Jales AR; Brandt W; Lewis JW; Husbands SM
J Med Chem; 2003 Jan; 46(2):314-7. PubMed ID: 12519069
[TBL] [Abstract][Full Text] [Related]
28. Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state.
Narita M; Kishimoto Y; Ise Y; Yajima Y; Misawa K; Suzuki T
Neuropsychopharmacology; 2005 Jan; 30(1):111-8. PubMed ID: 15257306
[TBL] [Abstract][Full Text] [Related]
29. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
Paronis CA; Waddell AB; Holtzman SG
Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
[TBL] [Abstract][Full Text] [Related]
30. Selective kappa-opioid antagonists related to naltrindole. Effect of side-chain spacer in the 5'-amidinoalkyl series.
Jales AR; Husbands SM; Lewis JW
Bioorg Med Chem Lett; 2000 Oct; 10(20):2259-61. PubMed ID: 11055333
[TBL] [Abstract][Full Text] [Related]
31. Substance P antagonists: meet the new drugs, same as the old drugs? Insights from transgenic animal models.
Santarelli L; Saxe MD
CNS Spectr; 2003 Aug; 8(8):589-96. PubMed ID: 12907922
[TBL] [Abstract][Full Text] [Related]
32. Role of kappa-opioid receptors in stress and anxiety-related behavior.
Van't Veer A; Carlezon WA
Psychopharmacology (Berl); 2013 Oct; 229(3):435-52. PubMed ID: 23836029
[TBL] [Abstract][Full Text] [Related]
33. 5-(4-hydroxy-3-dimethoxybenzylidene)-rhodanine (RD-1)-improved mitochondrial function prevents anxiety- and depressive-like states induced by chronic corticosterone injections in mice.
Yang N; Ren Z; Zheng J; Feng L; Li D; Gao K; Zhang L; Liu Y; Zuo P
Neuropharmacology; 2016 Jun; 105():587-593. PubMed ID: 26926430
[TBL] [Abstract][Full Text] [Related]
34. Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link.
Stahl SM
J Clin Psychiatry; 1997; 58 Suppl 8():20-6. PubMed ID: 9236732
[TBL] [Abstract][Full Text] [Related]
35. Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice.
Lesscher HM; Bailey A; Burbach JP; Van Ree JM; Kitchen I; Gerrits MA
Eur J Neurosci; 2003 Mar; 17(5):1006-12. PubMed ID: 12653976
[TBL] [Abstract][Full Text] [Related]
36. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms.
DeRubeis RJ; Siegle GJ; Hollon SD
Nat Rev Neurosci; 2008 Oct; 9(10):788-96. PubMed ID: 18784657
[TBL] [Abstract][Full Text] [Related]
37. Schild (apparent pA2) analysis of a kappa-opioid antagonist in Planaria.
Raffa RB; Baron DA; Tallarida RJ
Eur J Pharmacol; 2006 Jul; 540(1-3):200-1. PubMed ID: 16737694
[TBL] [Abstract][Full Text] [Related]
38. The dynamic relationship between mu and kappa opioid receptors in body temperature regulation.
Chen X; McClatchy DB; Geller EB; Tallarida RJ; Adler MW
Life Sci; 2005 Dec; 78(4):329-33. PubMed ID: 16257420
[TBL] [Abstract][Full Text] [Related]
39. Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.
Lalanne L; Ayranci G; Filliol D; Gavériaux-Ruff C; Befort K; Kieffer BL; Lutz PE
Addict Biol; 2017 Jul; 22(4):1010-1021. PubMed ID: 27001273
[TBL] [Abstract][Full Text] [Related]
40. A Statement on the Pharmacology of Reinstatement: Naltrexone and Relapse to Opioid Seeking.
Barrett JE
J Pharmacol Exp Ther; 2024 Mar; 389(1):1-4. PubMed ID: 38490723
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
